Retention enhancement by pre-test beta-endorphin and oxotremorine and its reversal by scopolamine.
The pre-test administration of beta-endorphin (0.05 microgram/mouse), oxotremorine sesquifumarate (5.0 micrograms/mouse), or beta-endorphin plus oxotremorine enhanced retention test performance of a conditioned emotional response in mice. The effects were blocked by scopolamine. Scopolamine had no effect of its own. The data suggest that the retention enhancement caused by beta-endorphin may involve the secondary activation of cholinergic mechanisms.
Brioni
J D
JD
Center for the Neurobiology of Learning and Memory, University of California, Irvine 92717.
Izquierdo
I
I
D000818:Animals; D001143:Arousal / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D003214:Conditioning, Classical / Q000187:drug effects*; D004193:Discrimination Learning / Q000187:drug effects; D008297:Male; D008568:Memory / Q000187:drug effects*; D011939:Mental Recall / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D010095:Oxotremorine / Q000031:analogs & derivatives / Q000494:pharmacology; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D011976:Receptors, Muscarinic / Q000187:drug effects; D011957:Receptors, Opioid / Q000187:drug effects; D012153:Retention, Psychology / Q000187:drug effects*; D012601:Scopolamine / Q000494:pharmacology; D001615:beta-Endorphin / Q000494:pharmacology*
D011943:Receptors, Adrenergic, beta; D011976:Receptors, Muscarinic; D011957:Receptors, Opioid; C049425:oxotremorine sesquifumarate; D010095:Oxotremorine; D001615:beta-Endorphin; D012601:Scopolamine